Primary Hypercholesterolaemia
3
Pipeline Programs
2
Companies
2
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
U
NIACINApproved
niacin
Unknown CompanyNicotinic Acid [EPC]oral2022
U
NIACORApproved
niacin
Unknown CompanyNicotinic Acid [EPC]oral2000
Competitive Landscape
2 companies ranked by most advanced pipeline stage
M&
DS
Daiichi SankyoChina - Shanghai
1 programCombination of bempedoic acid and ezetimibeN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Merck & Co.niacin
Daiichi SankyoCombination of bempedoic acid and ezetimibe
Clinical Trials (2)
Total enrollment: 4,180 patients across 2 trials
Lipid Efficacy/Tolerability Study (0524A-020)
Start: Dec 2005Est. completion: Dec 20061,620 patients
Phase 3Completed
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
Start: Jan 2026Est. completion: Mar 20292,560 patients
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space